Lovastatin in X-Linked Adrenoleukodystrophy

Authors:
  • MEMarc Engelen
    Marc Engelen
  • RORob Ofman
    Rob Ofman
  • MDMarcel G.W. Dijkgraaf
    Marcel G.W. Dijkgraaf
  • MHMichiel Hijzen
    Michiel Hijzen
  • LWLucinda A. van der Wardt
    Lucinda A. van der Wardt
  • BGBjorn M. van Geel
    Bjorn M. van Geel
  • MVMarianne de Visser
    Marianne de Visser
  • RWRonald J.A. Wanders
    Ronald J.A. Wanders
  • BPBwee Tien Poll-The
    Bwee Tien Poll-The

Abstract
As reported previously in the Journal, lovastatin lowers levels of very-long-chain fatty acids in plasma in patients with X-linked adrenoleukodystrophy (X-ALD).1 Further studies did not reproduce this finding with the use of simvastatin in patients or with the use of lovastatin in X-ALD–knockout mice.2,3 Still, many patients with X-ALD worldwide receive lovastatin.